JN0003
Ridogrel
≥98% (HPLC)
别名:
5-[(E)-[3-pyridyl-[3-(trifluoromethyl)phenyl]methylene]amino]oxypentanoic acid, R 68070, R068070
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C18H17F3N2O3
化学文摘社编号:
分子量:
366.33
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
room temp
SMILES string
O=C(O)CCCCO/N=C(C1=CC=CN=C1)\C2=CC=CC(C(F)(F)F)=C2
InChI
1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17-
InChI key
GLLPUTYLZIKEGF-QJOMJCCJSA-N
Biochem/physiol Actions
A2 receptor antagonist
Ridogrel is an orally active, potent and specific combined thromboxane synthase inhibitor and thromboxane A2 receptor ( thromboxane/prostaglandin endoperoxide receptor) antagonist. Ridogrel is a potent antiplatelet agent.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
E Carty et al.
Alimentary pharmacology & therapeutics, 14(6), 807-817 (2000-06-10)
Thromboxanes, prostaglandins, reactive oxygen metabolites and pro-inflammatory cytokines are produced in excess in inflammatory bowel disease. Preliminary reports suggest that ridogrel, a thromboxane synthesis inhibitor and receptor blocker, may have therapeutic benefits in ulcerative colitis. To investigate the anti-inflammatory profile
J J Auwerda et al.
European journal of gastroenterology & hepatology, 13(4), 397-400 (2001-05-08)
To evaluate the effect of Ridogrel enemas (Janssen Research Foundation, Beerse, Belgium) on disease activity and mucosal inflammatory mediators in patients with active left-sided ulcerative colitis. Eleven patients with active left-sided ulcerative colitis were evaluated in an open non-placebo-controlled pilot